Allogene on Wednesday released the first data on tumor responses to its off-the-shelf CAR-T cell therapy for an aggressive form of B-cell lymphoma, showing that at least some patients experienced complete remission.
The new data are preliminary but important because they represent potential progress for the CAR-T field. If successful, the Allogene treatment, called ALLO-501, could be widely available and allow patients with advanced blood cancer to be treated on demand. Today’s bespoke CAR-Ts, by comparison, must be genetically engineered from each patient’s own cells.
About the Author Reprints
